Tuesday, January 26, 2021
Home Latest Pharma-News Merk's Strategic Investments from UPMC Enterprises for Infectious Diseases and Antimicrobial Stewardship

Merk’s Strategic Investments from UPMC Enterprises for Infectious Diseases and Antimicrobial Stewardship

May 19, 2020: “Merck and UPMC announced that Infectious Disease Connect Inc., a UPMC-backed company offering telemedicine-enabled solutions to hospitals for treatment of infectious diseases, has combined with Merck’s ILÚM Health Solutions, a provider of technology and services to support infectious disease management, clinical decision support and precision antibiotic therapy.

“The addition of ILÚM’s platform and capabilities arms Infectious Disease Connect’s physicians with an important tool to accelerate informed decision-making for the hospitals and patients they serve,” said David Zynn, president of Infectious Disease Connect.

“Combining our respective expertise and resources positions us to enhance the care of patients with infections, optimize antimicrobial therapy, lower costs and reduce the potential for drug resistance.”

- Advertisement -

As part of this agreement, UPMC Enterprises, the innovation and commercialization arm of UPMC, and Merck Global Health Innovation Fund each are investing $5 million to support the development of customer offerings and business growth for the newly combined entity.

UPMC will retain a majority stake in the combined company.

Infectious Disease Connect has established a telemedicine solution for infectious disease care enabling doctors to access the expertise of an infectious disease specialist to facilitate timely diagnosis and treatment of patients under their care.

With ILÚM’s platform, physicians and pharmacists will receive real-time antimicrobial usage and resistance data from partner hospitals to help them select appropriate therapy, while managing costs, toxicity and the potential for further resistance and transmission of infection.

ILÚM uses machine learning to evaluate a patient’s demographic factors, medication history, past hospitalizations and other data to generate individualized treatment recommendations.

ILÚM also has developed a public health surveillance platform in conjunction with the New York State Department of Health to track and limit the spread of drug-resistant organisms and other infectious disease threats, including COVID-19.

“The rising level of resistance to antimicrobials remains a serious threat to public health, food safety and global security,” said Paul Edwards, chief executive officer, ILÚM.

“This combination marries the excellence of Infectious Disease Connect’s physicians and telemedicine platform with the real-time intelligence needed to effectively manage increasingly complex and life-threatening infectious diseases, as seen in this current pandemic.”

With its expanded capabilities and efficiencies, the new Infectious Disease Connect aims to address the nationwide shortage of infectious disease physicians, the rapidly rising risk of hospital-acquired infections and inappropriate antimicrobial usage, which are estimated to cost hospitals more than $40 billion annually.

The company can provide hospitals with infectious disease expertise and tools to help meet new federal regulations requiring evidence-based antimicrobial stewardship programs that produce measurable results.

Infectious Disease Connect, headquartered in Pittsburgh, will continue to serve ILÚM’s hospital customers and integrate most of its employees.

The expanded company now serves hospitals in nine states.”
https://www.mrknewsroom.com/news-release/corporate-news/%C2%A0infectious-disease-connect-and-ilum-health-solutions-combine-advance-pr

LEAVE A REPLY

Please enter your comment!
Please enter your name here

14 + ten =

Most Popular

AZ’s Symbicort Turbuhaler approved as an anti-inflammatory reliever in mild asthma

January 26, 2021: "AstraZeneca’s Symbicort Turbuhaler (budesonide/formoterol 160/4.5mcg) has been approved in China as an anti-inflammatory reliever to be taken as-needed in response to...

Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia

January 25, 2021: "AstraZeneca’s Calquence (acalabrutinib), a next-generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult...

What is the process for Submission of Synopsis?

1.1 a. "Prior to submission of a thesis synopsis, a comprehensive assessment of the research work should be carried out by a...

COVAX Announces new agreement, plans for first deliveries

January 22, 2021: COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income...